Skip to main content
Clinical Trials/NCT04893837
NCT04893837
Completed
Not Applicable

Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)

University of Alabama at Birmingham2 sites in 1 country399 target enrollmentApril 18, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Brain Injuries, Traumatic
Sponsor
University of Alabama at Birmingham
Enrollment
399
Locations
2
Primary Endpoint
Diagnostic performance of the infrascanner
Status
Completed
Last Updated
8 months ago

Overview

Brief Summary

MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for the monitoring of traumatic intracranial hematomas.

Detailed Description

MOBI-1 is a single-arm, multi-center derivation / validation study that will evaluate the use of the Infrascanner for monitoring traumatic intracranial hematomas. All patients will receive standard care plus hourly infrascanner assessments. This study will test the hypotheses that: 1. The Infrascanner has sufficient diagnostic performance to detect the expansion of intracranial hematomas 2. Patients who have expanding intracranial hematomas will be identified faster when monitored with hourly infrascanner assessments compared to standard care alone 3. Clinical / research staff will be able to attain all data points and relay the assessments to the medical team.

Registry
clinicaltrials.gov
Start Date
April 18, 2022
End Date
August 25, 2025
Last Updated
8 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jan O. Jansen

Professor and Director, UAB Center for Injury Science

University of Alabama at Birmingham

Eligibility Criteria

Inclusion Criteria

  • Age 15 or older
  • Admission CT Scan shows intracranial hemorrhage
  • Glasgow Coma Scale less than 15
  • Neurosurgery service determines initial care is nonoperative
  • Admitted for observation for TBI, to either step-down unit or intensive care unit

Exclusion Criteria

  • Inability to provide informed consent or lack of a legally authorized representative (LAR)
  • Admitted and observed for \>2 hours prior to screening (i.e., has already received second neurological check)
  • Other injuries deemed non-survivable
  • Diagnosed with hemorrhagic shock or receives a large volume transfusion (\>3 units of any blood product within any 1 hour)
  • Planned surgical interventions/ procedures during study period (before the second CT scan)
  • Known prisoner

Outcomes

Primary Outcomes

Diagnostic performance of the infrascanner

Time Frame: Month 24

Number of participants whose Infrascan results were accurate

Secondary Outcomes

  • Time to detection of an enlarging hematoma(0-12 hours)

Study Sites (2)

Loading locations...

Similar Trials